Corticosteroid treatment of severe community-acquired pneumonia

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1233-1237

  Gorman, Sean K ^a,b   Slavik, Richard S ^a,b   Marin, Judith ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c FRASER HEALTH AUTHORITY   (Canada)

Author keywords

Glucocorticoids; Mechanical ventilation; Pneumonia

Indexed keywords

C REACTIVE PROTEIN; CEFOTAXIME; CHEMOKINE; CORTICOSTEROID; CYTOKINE; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLPREDNISOLONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

CELL MIGRATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; HOSPITAL DISCHARGE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MORTALITY; OXYGENATION; PRIORITY JOURNAL; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS;

EID: 34547146874     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H660     Document Type: Review

References (23)

1. Alberti C, Brun-Buisson C, Buchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-21.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
3. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
4. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
5. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
6. Macfarlane JT, Boswell T, Douglas G, et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56(suppl 4):1-64.
7. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37: 1405-33.
8. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia - results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 1997;157:36-44.
9. Leeper KV, Torres A. Community acquired pneumonia in the intensive care unit. Clin Chest Med 2002;28:108-21.
10. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokines expression in community-acquired pneumonia. Chest 1995;107: 1342-9.
11. Schutte H, Lohmeyer J, Rosseau S, et al. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J 1996;9:1858-67.
12. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokines expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999;27:1745-53.
13. Annane D. Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care 2005;11:449-53.
14. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004;329:480-9.
15. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 1999;160:1079-100.
16. Meduri GU, Headley S, Golden E, et al. Prolonged methylprednisolone treatment improves lung function and outcome of unresolving ARDS: a randomized, double-blind, placebo-controlled trial. JAMA 1998;280:159-65.
17. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001;12(suppl 17):S70-4.
18. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover trial. Am J Respir Crit Care Med 2003;167:512-20.
19. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165: 983-91.
20. Marik P, Kraus P, Sribante J, Havlick I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 1993;104:389-94.
21. Monton C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14:218-20.
22. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-8.
23. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44.